感染

订阅

MedSci主页 / 所有栏目 / 感染

Nature子刊：HIV疫苗开发突破性进展

2015-07-03 佚名 生物谷

HIV疫苗Env蛋白
关注

近日，刊登在国际杂志Nature Structural & Molecular Biology上的一篇研究报告中，来自杜克大学的研究者在HIV研究领域取得了突破性的成果，他们通过研究开发了一种的3D“设计师”蛋白，一旦将这种蛋白注射入HIV患者机体中，就会帮助患者机体免疫系统较好地制造抗体来抵御HIV的侵袭。目前全球超过3500万人感染HIV，而且每年都会有200万人死亡AIDS；一旦个体

近日，刊登在国际杂志Nature Structural & Molecular Biology上的一篇研究报告中，来自杜克大学的研究者在HIV研究领域取得了突破性的成果，他们通过研究开发了一种的3D“设计师”蛋白，一旦将这种蛋白注射入HIV患者机体中，就会帮助患者机体免疫系统较好地制造抗体来抵御HIV的侵袭。

目前全球超过3500万人感染HIV，而且每年都会有200万人死亡AIDS；一旦个体感染HIV，抗逆转录病毒药物可以抑制感染者机体病毒的复制，但仅有疫苗才可以阻断HIV在不同个体间的传播；疫苗可以通过诱发机体免疫系统制造抗体蛋白来抵御病毒感染，这些抗体会帮助机体抵御外来病毒，然而在HIV患者机体中病毒总会“欺骗”机体来得以存活繁衍。

HIV可以将其遗传物质掺入宿主细胞的DNA中，其会拦截宿主细胞的复制机器，驱动复制机器来帮助制造更多的病毒拷贝，早在20世纪90年代，研究者就发现一部分感染HIV的个体的机体中会产生特殊抗体来帮助其机体抵御不同毒株的侵袭。这种广谱型中和性抗体会固定在病毒表面，就好象锁和钥匙一样，从而抗体就会抑制病毒侵染其它细胞。

但HIV常常会通过这些抗体来躲避机体的监测，因为HIV表面对攻击非常敏感的外膜会不断改变其形状；为了克服这个问题，这项研究中研究人员对名为Env的HIV表面的刺突状蛋白进行了研究，在3D打印技术的帮助下，研究人员开发了一种评分系统，同时根据抗体和病毒的结合情况开发出了一系列额定数量的抗体，研究者表示，我们鉴别的Env蛋白的特殊构象就可以帮助寻找那些有效的抗体和无任何作用的抗体。

随后研究者在Env蛋白理想的形状下鉴别出可以有效沉默该蛋白表达的特殊氨基酸序列改变；研究者表示，一旦将Env蛋白注射到患者机体中，其就会诱导机体免疫系统优先产生最为有效的抗体；最后研究者Donald说道，我们的想法就是锁定Env蛋白，使其不能过渡到其它的构象状态，从而使得有效的抗体同其结合，最终抑制HIV的繁殖扩散。

原始出处：

Young Do Kwon, Marie Pancera, Priyamvada Acharya, Ivelin S Georgiev, Emma T Crooks, Jason Gorman, M Gordon Joyce, Miklos Guttman, Xiaochu Ma, Sandeep Narpala, Cinque Soto, Daniel S Terry, Yongping Yang, Tongqing Zhou, Goran Ahlsen, Robert T Bailer, Michael Chambers, Gwo-Yu Chuang, Nicole A Doria-Rose, Aliaksandr Druz, Mark A Hallen, Adam Harned, Tatsiana Kirys, Mark K Louder, Sijy O'Dell et al.Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.Nature Structural & Molecular Biology.June 22, 2015.doi:10.1038/nsmb.3051

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-12-19 liye789132251

    #Nat#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-11-15 zhangfeng224558

    it is good idea

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-09 lovejing

    相应对乙肝患者也应该适用吧

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-05 ms306040998833292

    #HIV疫苗#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    厉害

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-03 caierhong

    期待

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=59804, encodeId=1f9e598048c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59805, encodeId=a04b59805d2, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:55:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880715, encodeId=b8da1880e1576, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 19 11:04:00 CST 2015, time=2015-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43220, encodeId=e00a4322000, content=it is good idea, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e921663400, createdName=zhangfeng224558, createdTime=Sun Nov 15 10:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32179, encodeId=5294321e9fd, content=相应对乙肝患者也应该适用吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Thu Jul 09 22:44:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479677, encodeId=224914e9677f4, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Sun Jul 05 04:04:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30493, encodeId=c56f3049303, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:52:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30359, encodeId=3dd730359ea, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30339, encodeId=504630339e5, content=这个药物的设计非常非常巧妙，应该很有前途。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:14:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-03 lovetcm

    这个药物的设计非常非常巧妙，应该很有前途。

    0

相关资讯

Cell：揭秘HIV广泛中和抗体家族

　　来自美国斯克里普斯研究所（TSRI）的科学家们发现，一个可广泛中和不同艾滋病毒株的抗体家族演变出了显著不同的结构来攻击病毒上的一个脆弱位点。研究结果为未来的HIV疫苗设计提供了一些新线索。相关论文在9月25日《细胞》（Cell）杂志上。 　　斯克里普斯研究所Skaggs化学生物学研究所成员、结构生物学教授 Ian Wilson